You may not know that Taiwan produces nearly 1,607 metric tons of hazardous medical waste each year, enough to go around the Earth's equator in more than one circle, and cover 89 101 buildings, which doesn't even include the cost of hospital personnel, *** processing costs, the social resources consumed by medical waste, in order to reduce the burden of healthcare costs, has become an unavoidable trend, but also is exactly the This is a major issue for countries around the world, and the establishment of a new technology is effectively changing this situation.
Inhua Biotech Pharmaceutical Co., Ltd. owns the patent technology of "OralPAS", which has been successfully passed by the U.S. Food and Drug Administration (FDA) to enter the human clinical trial on September 9, 2011. Oral is a technology that can be penetrated and absorbed through oral administration. This technology platform will open the door for global biotechnology to move towards a new direction of "green healthcare".
"OralPAS?" technology has been developed specifically for the development of drug delivery systems for drugs that are not easily absorbed. In addition, Inovar is targeting the development of special drugs such as cancer drugs and immunosuppressive drugs. Inhua Biotech & Pharmaceutical Co., Ltd. will announce this unique new technology - treating cancer as a chronic disease. This patented technology platform can be applied to the research and development of new formulations for drugs with high formulation difficulties, and to the subsequent listing and marketing, and it can also be used in the development of new drugs and the design of new drug dosage forms, so that, if the research of anticancer drugs is successful, the patients do not need to go to hospitals to do chemotherapy, but can take oral drugs instead. If the anti-cancer drug research is successful, patients will not have to go to the hospital for chemotherapy, but can switch to the oral way to maintain good blood concentration, treating cancer as a chronic disease can also reduce medical costs and medical risks, and in the future, it will be more able to create a single drug development authorization can be as high as 30 million U.S. dollars in value; this technology and the FDA approval case has been successful in attracting the international pharmaceutical companies, and in the future there is definitely an opportunity to develop into a bright light of Taiwan's biotechnology.
Subscribe to the Healthy Love LOHAS audio-visual channel to read health knowledge more easily Join in and pay attention to your health every day! LINE@ ID:@ : /cancer/article/729/oral instead of injections Creating green healthcare Keywords: OralPAS, needle drugs, oral drugs, Inhua Biotech